Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Hong Kong Med J ; 26(1): 56-65, 2020 02.
Article in English | MEDLINE | ID: mdl-32077861

ABSTRACT

OBJECTIVES: Juvenile idiopathic arthritis (JIA) is the most common type of inflammatory arthritis in children. Treatment options have been expanded since the introduction of biologics, which are highly effective. The existing local JIA treatment guideline was published more than a decade ago, when use of biologics was not as common. In this article, we review the latest evidence on using biologics in three JIA subtypes: JIA of polyarticular course (pcJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA). Based on the latest information, an update on eligibility, response assessment, termination, and safety information for using biologics in these patients was performed. CONSENSUS PROCESS: The JIA Work Group, which consisted of nine paediatricians experienced in managing JIA, was convened in 2016. Publications before July 2017 were screened. Eligible articles were clinical trials, extension studies, systemic reviews, and recommendations from international societies and regulatory agencies about the use of biologics in pcJIA, ERA, and PsA. Evidence extraction, appraisal, and drafting of propositions were performed by two reviewers. Extracted evidence and drafted propositions were presented and discussed at the first two meetings. Overwhelming consensus was obtained at the final meeting in May 2018. Seven practice consensus statements were formulated. Regular review should be performed to keep the practice evidence-based and up-to-date.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/drug therapy , Arthritis, Psoriatic/drug therapy , Biological Products/therapeutic use , Antirheumatic Agents/adverse effects , Biological Products/adverse effects , Child , Consensus , Humans , Practice Guidelines as Topic , Randomized Controlled Trials as Topic
3.
J Hosp Infect ; 58(2): 146-50, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15474186

ABSTRACT

A screening programme for expressed breast milk (EBM) revealed the alarming fact that our study group had the highest rate of contamination ever reported. The programme started in July 2002 and involved a group of Chinese women whose premature babies were in the neonatal intensive care unit. EBM was considered to be contaminated if there was any growth of pathogens, including Gram-negative bacteria, enterococci or Staphylococcus aureus, or if the total bacterial count was >10(5) cfu/mL. Of 59 samples from 23 mothers, 63% were contaminated. This high contamination rate could be due to the Chinese tradition of avoiding bathing for one month after childbirth. Previous studies have shown that feeding EBM rather than premature infant formula milk has advantages in terms of decreased incidence of necrotizing enterocolitis and neonatal sepsis. However, in this population, with such a high incidence of contaminated EBM, this may not be the case. Further studies to compare EBM with premature infant formula in this population are required.


Subject(s)
Cross Infection/epidemiology , Cross Infection/microbiology , Enterocolitis, Necrotizing/epidemiology , Enterocolitis, Necrotizing/microbiology , Food Microbiology , Infant Nutritional Physiological Phenomena , Infant, Low Birth Weight , Infant, Premature , Milk, Human/microbiology , Adult , China/epidemiology , Cross Infection/etiology , Enterocolitis, Necrotizing/etiology , Female , Food Contamination , Gram-Negative Bacteria/isolation & purification , Humans , Incidence , Infant, Newborn , Intensive Care Units, Neonatal/statistics & numerical data , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...